COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00241371
Recruitment Status : Terminated (No response seen in patients)
First Posted : October 18, 2005
Last Update Posted : August 13, 2013
Information provided by (Responsible Party):
Washington University School of Medicine

Brief Summary:
To determine the overall response rate (CR+PR) of patients with relapsed or refractory multiple myeloma treated with clofarabine.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Clofarabine Phase 2

Detailed Description:

To determine the time to response, duration of response, and time to progression of patients treated with clofarabine.

To determine the safety and tolerability of clofarabine in these patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma
Study Start Date : March 2005
Actual Primary Completion Date : November 2005
Actual Study Completion Date : December 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma
Drug Information available for: Clofarabine

Arm Intervention/treatment
Experimental: Clofarabine
4 mg/m2 IV over 1 hour on days 1-5 of each 28 day cycle.
Drug: Clofarabine

Primary Outcome Measures :
  1. Overall response rate (CR+PR) [ Time Frame: Every 3 months ]

Secondary Outcome Measures :
  1. Time to response [ Time Frame: Every 3 months ]
  2. Safety and tolerability of clofarabine [ Time Frame: 30 days after last treatment ]
  3. Duration of response [ Time Frame: Every 3 months ]
  4. Time to progression [ Time Frame: Every 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Multiple myeloma diagnosed by standard criteria.
  2. Measurable levels of monoclonal protein in serum (>= 0.5 g/dL) or urine (>= 0.2 g/24 hr).
  3. At least 1 prior therapies for multiple myeloma with documented evidence of progression on the most recent treatment.
  4. Age 18 years or older.
  5. ECOG performance status <= 2.
  6. Acceptable organ and marrow function as defined below:

    • Hemoglobin >= 8 gm/dL
    • Absolute neutrophil count >= 1,000/mm3
    • Platelets >= 50,000/mm3
    • Total bilirubin <= 2.5 X institutional upper limit of normal
    • AST, ALT <= 2.5 X institutional upper limit of normal
    • Creatinine 1.5 x institutional upper limit of normal
    • Normal cardiac function as determined by standard institutional methods
  7. Women of child bearing potential must agree to use adequate contraception prior to study entry and for the duration of study.
  8. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  1. Receiving any other investigational agents.
  2. Receiving concurrent steroids with a dose equivalent of prednisone of >= 150 mg/month.
  3. Pregnant or nursing.
  4. Active systemic infection considered opportunistic, life threatening or clinically significant at the time of treatment.
  5. Severe concurrent disease, including severe insulin-dependent diabetes, uncontrolled hypertension, transient ischemic attacks, uncontrolled symptomatic coronary artery disease, or symptomatic CNS involvement or psychiatric illness/social situations that would limit compliance with study requirements.
  6. History of other malignancy except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast unless the subject has been off treatment and free from disease for >= 3 years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00241371

Layout table for location information
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
Sponsors and Collaborators
Washington University School of Medicine
Layout table for investigator information
Principal Investigator: Ravi Vij, M.D. Washington University School of Medicine

Additional Information:
Layout table for additonal information
Responsible Party: Washington University School of Medicine Identifier: NCT00241371    
Other Study ID Numbers: 04-0916
First Posted: October 18, 2005    Key Record Dates
Last Update Posted: August 13, 2013
Last Verified: August 2013
Keywords provided by Washington University School of Medicine:
Multiple Myeloma
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents